Ventus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Article content

WALTHAM, Mass. & MONTREAL — Ventus Therapeutics, a clinical-stage biopharmaceutical company utilizing its proprietary structural biology and computational chemistry platform, ReSOLVE^TM, to develop differentiated small molecule therapeutics, announced today that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 10:30 a.m. PST.

Article content

About Ventus Therapeutics

Article content

Ventus Therapeutics is a clinical-stage biopharmaceutical company deploying leading-edge structural biology and computational chemistry tools to create novel small molecule medicines for challenging targets in immunology, inflammation, and neurology. The company’s proprietary drug discovery platform, ReSOLVE^TM, gives it the ability to discover and develop medicines through unique insights into protein targets and to create dynamic hydrocophore™ blueprints that can guide the development of differentiated therapies at a fast pace. Ventus’ first target screen was conducted in 2020, which led to the nomination of three development candidates in 2022, including: VENT-03, a first-in-class cGAS inhibitor; VENT-02, a brain-penetrant NLRP3 inhibitor; and VENT-01, a peripherally restricted NLRP3 inhibitor. Ventus entered the clinic with its most advanced program, VENT-02, in 2023, and the Phase 1 clinical trial is ongoing. These programs exemplify Ventus’ robust discovery capabilities and focus on differentiated programs for multi-indication immunology and neurology targets. For more information, please visit www.ventustx.com and engage with Ventus on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements about future expectations, plans, and prospects, including, but not limited to, statements related to the anticipated benefits of Ventus’ business strategy, pipeline programs, drug discovery platform, and financial…